| The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. | |
| | |
MedLine Citation:
|
PMID: 15043515 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications. AIM: To test this hypothesis for intestinal resection in a cohort of 313 Crohn's disease patients treated with infliximab. Forty received one or more infusions prior to intestinal resection (31/40 within 12 weeks). METHODS: The post-operative events of these patients were compared with those of a control group (infliximab naive) of 39 patients adjusted for age, gender and surgical procedure. Early (10 days) and late (3 months) major or minor complications were identified. RESULTS: The incidence of early minor (15.0% vs. 12.8%) and major (12.5% vs. 7.7%) and late minor (2.5% vs. 5.1%) and major (17.5% vs. 12.8%) complications and the mean hospital stay after surgery (10.3 +/- 4.0 days vs. 9.9 +/- 5.5 days) were similar in both groups. A trend towards an increased early infection rate was found in infliximab pre-treated patients (6 vs. 1; P = 0.10), but more patients in this group received corticosteroids and/or immunosuppressives (29 vs. 16 patients; P < 0.05). CONCLUSION: The use of infliximab before intestinal resection does not prolong the hospital stay and does not increase the rate of post-operative complications. |
| | |
Authors:
|
L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts |
Related Documents
:
|
10400415 - Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage c... 19078465 - Mycobacterium avium/mycobacterium intracellulare complex-associated arthritis masquerad... 23236315 - Cervical artificial disc replacement versus fusion in the cervical spine: a systematic ... 23327295 - Haloperidol prophylaxis in critically ill patients with a high risk for delirium. 18351365 - Outcome in neonates with esophageal atresia treated over the last 20 years. 21561545 - Clinical outcome of diabetic peritoneal dialysis patients and evaluation of factors aff... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 19 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-03-26 Completed Date: 2004-07-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 749-54 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antibodies, Monoclonal / adverse effects* Cohort Studies Crohn Disease / surgery* Female Gastrointestinal Agents / adverse effects* Humans Male Middle Aged Postoperative Complications / chemically induced* Retrospective Studies Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colit...
Next Document: Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.